Αρχική World News Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in... World News Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Από Ogkologos - 7 Σεπτεμβρίου, 2026 150 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-671 study after 5 years of follow-up Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas 21 Δεκεμβρίου, 2022 New on NCI’s Websites for September 2020 2 Σεπτεμβρίου, 2020 Keeping progress in oncology on the agenda: ESMO honours recipients of... 3 Δεκεμβρίου, 2020 The ‘major conditions strategy’: will ministers fail to give cancer the... 6 Φεβρουαρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS How to Cope With Panic Attacks During Cancer New on NCI’s Websites for September 2022 AI-Based Score as a Selection Tool for Supplemental MRI After Negative... Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma